Abstract:Importance:It is unclear whether female carriers of the apolipoprotein E (APOE) ε4 allele are at greater risk of developing Alzheimer disease (AD) than men, and the sex-dependent association of mild cognitive impairment (MCI) and APOE has not been established.Objective:To determine how sex and APOE genotype affect the risks for developing MCI and AD.Data Sources:Twenty-seven independent research studies in the Global Alzheimer's Association Interactive Network with data on nearly 58 000 participants.Study Selection:Non-Hispanic white individuals with clinical diagnostic and APOE genotype data.Data Extraction and Synthesis:Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks.Main Outcomes and Measures:Age-adjusted odds ratios (ORs) and 95% confidence intervals for developing MCI and AD were calculated for men and women across APOE genotypes.Results:Participants were men and women between ages 55 and 85 years. Across data sets most participants were white, and for many participants, racial/ethnic information was either not collected or not known. Men (OR, 3.09; 95% CI, 2.79-3.42) and women (OR, 3.31; CI, 3.03-3.61) with the APOE ε3/ε4 genotype from ages 55 to 85 years did not show a difference in AD risk; however, women had an increased risk compared with men between the ages of 65 and 75 years (women, OR, 4.37; 95% CI, 3.82-5.00; men, OR, 3.14; 95% CI, 2.68-3.67; P = .002). Men with APOE ε3/ε4 had an increased risk of AD compared with men with APOE ε3/ε3. The APOE ε2/ε3 genotype conferred a protective effect on women (OR, 0.51; 95% CI, 0.43-0.61) decreasing their risk of AD more (P value = .01) than men (OR, 0.71; 95% CI, 0.60-0.85). There was no difference between men with APOE ε3/ε4 (OR, 1.55; 95% CI, 1.36-1.76) and women (OR, 1.60; 95% CI, 1.43-1.81) in their risk of developing MCI between the ages of 55 and 85 years, but women had an increased risk between 55 and 70 years (women, OR, 1.43; 95% CI, 1.19-1.73; men, OR, 1.07; 95% CI, 0.87-1.30; P = .05). There were no significant differences between men and women in their risks for converting from MCI to AD between the ages of 55 and 85 years. Individuals with APOE ε4/ε4 showed increased risks vs individuals with ε3/ε4, but no significant differences between men and women with ε4/ε4 were seen.Conclusions and Relevance:Contrary to long-standing views, men and women with the APOE ε3/ε4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages.

APOE α4 homozygosity — a genetic form of Alzheimer disease?

APOE4 homozygosity is a new genetic form of Alzheimer's disease

The APOE ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease

APOEε4 and risk of Alzheimer's disease – time to move forward

Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele

Multifaceted roles of APOE in Alzheimer disease

A multi‐hit hypothesis for an APOE4‐dependent pathophysiological state

Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer’s Disease Spectrum

APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles

The ε4‐bearing TOMM40‐APOE‐APOC1 haplotype but not the ε4 allele confers an exceptionally high risk of Alzheimer’s disease

Apolipoprotein E in Alzheimer's disease: an update.

Prevalence Of The Apolipoprotein E Epsilon 4 Allele In Amyloid Beta Positive Subjects Across The Spectrum Of Alzheimer'S Disease

The Molecular Basis for Apolipoprotein E4 As the Major Risk Factor for Late-Onset Alzheimer's Disease

Human Glia‐specific Functional Dysregulations Affected by APOE Ε4 Risk of Alzheimer's Disease

Apolipoprotein E allelotype is associated with neuropathological findings in Alzheimer's disease

APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer's Disease pathology

Apolipoprotein &#x0395; Ε4 Frequency is Increased among Chinese Patients with Frontotemporal Dementia and Alzheimer's Disease

Function of apolipoprotein E in Alzheimer disease

ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis

Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis.

ApoE4: an emerging therapeutic target for Alzheimer’s disease